Protean proteases: At the cutting edge of lung diseases

Clifford Taggart, Marcus A. Mall, Gilles Lalmanach, Didier Cataldo, Andreas Ludwig, Sabina Janciauskiene, Nicole Heath, Silke Meiners, Christopher M. Overall, Carsten Schultz, Boris Turk, Keren S. Borensztajn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Proteases were traditionally viewed as mere protein-degrading enzymes with a very restricted spectrum of substrates. A major expansion in protease research has uncovered a variety of novel substrates, and it is now evident that proteases are critical pleiotropic actors orchestrating pathophysiological processes. Recent findings evidenced that the net proteolytic activity also relies upon interconnections between different protease and protease inhibitor families in the protease web. In this review, we provide an overview of these novel concepts with a particular focus on pulmonary pathophysiology. We describe the emerging roles of several protease families including cysteine and serine proteases. The complexity of the protease web is exemplified in the light of multidimensional regulation of serine protease activity by matrix metalloproteases through cognate serine protease inhibitor processing. Finally, we will highlight how deregulated protease activity during pulmonary pathogenesis may be exploited for diagnosis/prognosis purposes, and utilised as a therapeutic tool using nanotechnologies. Considering proteases as part of an integrative biology perspective may pave the way for the development of new therapeutic targets to treat pulmonary diseases related to intrinsic protease deregulation.

Original languageEnglish (US)
Article number1501200
JournalEuropean Respiratory Journal
Volume49
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Lung Diseases
Peptide Hydrolases
Serine Proteases
Lung
Nanotechnology
Serine Proteinase Inhibitors
Cysteine Proteases
Metalloproteases
Protease Inhibitors
Enzymes
Therapeutics
Research

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Taggart, C., Mall, M. A., Lalmanach, G., Cataldo, D., Ludwig, A., Janciauskiene, S., ... Borensztajn, K. S. (2017). Protean proteases: At the cutting edge of lung diseases. European Respiratory Journal, 49(2), [1501200]. https://doi.org/10.1183/13993003.01200-2015

Protean proteases : At the cutting edge of lung diseases. / Taggart, Clifford; Mall, Marcus A.; Lalmanach, Gilles; Cataldo, Didier; Ludwig, Andreas; Janciauskiene, Sabina; Heath, Nicole; Meiners, Silke; Overall, Christopher M.; Schultz, Carsten; Turk, Boris; Borensztajn, Keren S.

In: European Respiratory Journal, Vol. 49, No. 2, 1501200, 01.02.2017.

Research output: Contribution to journalArticle

Taggart, C, Mall, MA, Lalmanach, G, Cataldo, D, Ludwig, A, Janciauskiene, S, Heath, N, Meiners, S, Overall, CM, Schultz, C, Turk, B & Borensztajn, KS 2017, 'Protean proteases: At the cutting edge of lung diseases', European Respiratory Journal, vol. 49, no. 2, 1501200. https://doi.org/10.1183/13993003.01200-2015
Taggart C, Mall MA, Lalmanach G, Cataldo D, Ludwig A, Janciauskiene S et al. Protean proteases: At the cutting edge of lung diseases. European Respiratory Journal. 2017 Feb 1;49(2). 1501200. https://doi.org/10.1183/13993003.01200-2015
Taggart, Clifford ; Mall, Marcus A. ; Lalmanach, Gilles ; Cataldo, Didier ; Ludwig, Andreas ; Janciauskiene, Sabina ; Heath, Nicole ; Meiners, Silke ; Overall, Christopher M. ; Schultz, Carsten ; Turk, Boris ; Borensztajn, Keren S. / Protean proteases : At the cutting edge of lung diseases. In: European Respiratory Journal. 2017 ; Vol. 49, No. 2.
@article{2ce9d52a81cc4e86bf7c5df75371da74,
title = "Protean proteases: At the cutting edge of lung diseases",
abstract = "Proteases were traditionally viewed as mere protein-degrading enzymes with a very restricted spectrum of substrates. A major expansion in protease research has uncovered a variety of novel substrates, and it is now evident that proteases are critical pleiotropic actors orchestrating pathophysiological processes. Recent findings evidenced that the net proteolytic activity also relies upon interconnections between different protease and protease inhibitor families in the protease web. In this review, we provide an overview of these novel concepts with a particular focus on pulmonary pathophysiology. We describe the emerging roles of several protease families including cysteine and serine proteases. The complexity of the protease web is exemplified in the light of multidimensional regulation of serine protease activity by matrix metalloproteases through cognate serine protease inhibitor processing. Finally, we will highlight how deregulated protease activity during pulmonary pathogenesis may be exploited for diagnosis/prognosis purposes, and utilised as a therapeutic tool using nanotechnologies. Considering proteases as part of an integrative biology perspective may pave the way for the development of new therapeutic targets to treat pulmonary diseases related to intrinsic protease deregulation.",
author = "Clifford Taggart and Mall, {Marcus A.} and Gilles Lalmanach and Didier Cataldo and Andreas Ludwig and Sabina Janciauskiene and Nicole Heath and Silke Meiners and Overall, {Christopher M.} and Carsten Schultz and Boris Turk and Borensztajn, {Keren S.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1183/13993003.01200-2015",
language = "English (US)",
volume = "49",
journal = "European Respiratory Journal, Supplement",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - Protean proteases

T2 - At the cutting edge of lung diseases

AU - Taggart, Clifford

AU - Mall, Marcus A.

AU - Lalmanach, Gilles

AU - Cataldo, Didier

AU - Ludwig, Andreas

AU - Janciauskiene, Sabina

AU - Heath, Nicole

AU - Meiners, Silke

AU - Overall, Christopher M.

AU - Schultz, Carsten

AU - Turk, Boris

AU - Borensztajn, Keren S.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Proteases were traditionally viewed as mere protein-degrading enzymes with a very restricted spectrum of substrates. A major expansion in protease research has uncovered a variety of novel substrates, and it is now evident that proteases are critical pleiotropic actors orchestrating pathophysiological processes. Recent findings evidenced that the net proteolytic activity also relies upon interconnections between different protease and protease inhibitor families in the protease web. In this review, we provide an overview of these novel concepts with a particular focus on pulmonary pathophysiology. We describe the emerging roles of several protease families including cysteine and serine proteases. The complexity of the protease web is exemplified in the light of multidimensional regulation of serine protease activity by matrix metalloproteases through cognate serine protease inhibitor processing. Finally, we will highlight how deregulated protease activity during pulmonary pathogenesis may be exploited for diagnosis/prognosis purposes, and utilised as a therapeutic tool using nanotechnologies. Considering proteases as part of an integrative biology perspective may pave the way for the development of new therapeutic targets to treat pulmonary diseases related to intrinsic protease deregulation.

AB - Proteases were traditionally viewed as mere protein-degrading enzymes with a very restricted spectrum of substrates. A major expansion in protease research has uncovered a variety of novel substrates, and it is now evident that proteases are critical pleiotropic actors orchestrating pathophysiological processes. Recent findings evidenced that the net proteolytic activity also relies upon interconnections between different protease and protease inhibitor families in the protease web. In this review, we provide an overview of these novel concepts with a particular focus on pulmonary pathophysiology. We describe the emerging roles of several protease families including cysteine and serine proteases. The complexity of the protease web is exemplified in the light of multidimensional regulation of serine protease activity by matrix metalloproteases through cognate serine protease inhibitor processing. Finally, we will highlight how deregulated protease activity during pulmonary pathogenesis may be exploited for diagnosis/prognosis purposes, and utilised as a therapeutic tool using nanotechnologies. Considering proteases as part of an integrative biology perspective may pave the way for the development of new therapeutic targets to treat pulmonary diseases related to intrinsic protease deregulation.

UR - http://www.scopus.com/inward/record.url?scp=85013421980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013421980&partnerID=8YFLogxK

U2 - 10.1183/13993003.01200-2015

DO - 10.1183/13993003.01200-2015

M3 - Article

C2 - 28179435

AN - SCOPUS:85013421980

VL - 49

JO - European Respiratory Journal, Supplement

JF - European Respiratory Journal, Supplement

SN - 0903-1936

IS - 2

M1 - 1501200

ER -